viewDirecta Plus PLC

Directa Plus to target vehicle tyre market after latest patent award

Adding Directa’s Graphene Plus (G+) to tyres both reduces resistance and increases grip,

Less resistance and more grip with graphene

Directa Plus Plc (LON:DCTA) has been awarded a patent in Italy for a graphene-based solution that enhances the performance of tyres.

“Specifically, the patent covers Directa Plus' elastomeric composition comprising graphene and tyre components,” said the AIM-listed company.

READ: Directa reveals new G+ textile collaborations

Incorporating Directa’s Graphene Plus (G+) both reduces resistance and increases grip, making safer to turn while braking and in difficult weather.

Due to the reduced resistance, G+ also reduces fuel consumption and increases a tyre’s life.

Directa is already supplying graphene-enhancements to cycle tyre maker Vittoria, but the receipt of this patent means it can expand the roll-out of G+ tyres to the global automobile and motorcycle industries.

WATCH: Directa Plus secures two critical patents for Graphene Plus (G+)

Giulio Cesareo, Directa Plus’s chief executive, added: "The push for fuel efficiency from consumers and environmental groups means there is a growing demand for eco-friendly tyres.

“The unique qualities of G+ have been validated in bicycle tyres through our commercial partnership with Vittoria."


Quick facts: Directa Plus PLC

Price: 75.52 GBX

Market: AIM
Market Cap: £46.07 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Directa Plus PLC named herein, including the promotion by the Company of Directa Plus PLC in any Content on the Site, the Company receives from...



Investor Update: DeepMatter to collaborate with AstraZeneca

Headlines from the Proactive UK newsroom. DeepMatter (LON:DMTR) has agreed a tie-up with AstraZeneca to combine their drug development technology platforms. Deepmatter uses AI to monitor and record chemical reactions during drug development. Rare disease database group Open Orphan...

on 9/12/19

2 min read